Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review

Journal of Antimicrobial Chemotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 13, 2025

Abstract Background Persistent COVID-19 (pCOVID-19) in immunocompromised patients is characterized by unspecific symptoms and pulmonary infiltrates due to ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) replication. Treatment options remain unclear, leading different approaches, including combination therapy extended durations. The purpose of this study was assess the efficacy safety antiviral therapies for pCOVID-19 since Omicron surge. Methods We searched MEDLINE Scopus from 1 January 2022 6 August 2024 cohort studies case series on nirmatrelvir/ritonavir, remdesivir, ensitrelvir molnupiravir. Evidence certainty rated using Grading Recommendations Assessment, Development, Evaluation outcomes viral clearance, recurrence/relapse, mortality, adverse events (AEs) symptom resolution. Results Thirteen involving 127 cases were included. very low. In with at least two direct agents, clearance 79%, a 16% recurrence rate. All-cause mortality 9%, 6% while SARS-CoV-2 positive. 47 cases, AEs reported 11%. Symptom resolution ranged 3 days studies. one agent passive immunization, 89%, an 11% rate no deaths. four documented observed. monotherapy, 100%, 15% One death, unrelated SARS-CoV-2, occurred. 12 Conclusions Based low evidence, combining immunization resulted high rates few recurrences. occurred treated antivirals. Controlled are needed.

Language: Английский

Fresh frozen plasma for neutralizing SARS-CoV-2: “An exploratory cross-sectional study and review of the state of the art”

Enfermedades Infecciosas y Microbiología Clínica, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский